2019³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãá°èÇмú´ëȸ : 2019-03-22±³À°ÀÏÀÚ : 2019-03-22
±³À°Àå¼Ò : ¹Ð·¹´Ï¾ö ¼¿ï ÈúÆ°È£ÅÚ ÁöÇÏ 1Ãþ ±×·£µåº¼·ë
±³À°ÁÖÁ¦ :
2019³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãá°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ
´ã´çÀÚ : À̼¼Àº
¿¬¶ôó : 02-784-2742
À̸ÞÀÏ :
secretariat@kcnp.or.kr ±³À°Á¾·ù : Á¤½Å°Ç°ÀÇÇаú
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 12 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 80,000¿ø
ºñ°í »çÀüµî·Ïºñ Æò»ýȸ¿ø:¸éÁ¦/Á¤È¸¿ø:50,000/ºñȸ¿ø:60,000/ÁØȸ¿ø¹×±âŸ:30,000 ´çÀϵî·Ïºñ Æò»ýȸ¿ø:10,000/Á¤È¸¿ø:60,000/ºñȸ¿ø:80,000/ÁØȸ¿ø¹×±âŸ:40,000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 09:30~10:30 Á¤½Å°Ç°ÀÇÇаúÀÇ ¾ÈÀüÇÑ Áø·á ȯ°æÀ» À§ÇÑ Çö½ÇÀûÀÎ ´ëÃ¥ ÀÌ»ó¿(¿ø±¤ÀÇ´ë)
ÈÞ½Ä 03¿ù 22ÀÏ 10:30~10:50 ÈÞ½Ä ()
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 10:50~11:15 Brain energy metabolism and vulnerability to stress °¿ø¼·(°æÈñÀÇ´ë)
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 11:15~11:40 Diet and physical activity impact on mood disorder ±è¹ÎÇõ(¿¬¼¼¿øÁÖÀÇ´ë)
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 11:40~12:00 Brain mechanism of environmental risk for schizophrenia °½ÃÇö(±¹¸³Á¤½Å°Ç°¼¾ÅÍ)
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 10:50~11:15 Overview of resistant schizophrenia ÀÌÁß¼±(¿ï»êÀÇ´ë)
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 11:15~11:40 Pharmacological treatment for resistant schizophrenia ±è¼º¿Ï(Àü³²ÀÇ´ë)
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 11:40~12:00 Non-pharmacological treatment for resistant schizophrenia ÀÌÁ¤¼®(±¹¹Î°Ç°º¸ÇèÀϻ꺴¿ø)
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 12:00~12:30 Treatment strategy for young patients Á¤Á¾Çö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 12:30~13:00 Treatment strategy for schizophrenic patients who are intolerable to initial treatment ¹Ú¼º¿ë(°è¿äº´¿ø)
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 12:00~13:00 Optimal treatment of Brintellix: Translating clinical data into practice ÀÌÁ¤±¸(ÀÎÁ¦ÀÇ´ë)
ÈÞ½Ä 03¿ù 22ÀÏ 13:00~13:20 ÈÞ½Ä ()
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 13:20~13:45 Brexanolone iv for postpartum depression ¿ì¿µ¼·(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 13:45~14:10 Esketamine nasal spray for depression Á¤Çö°(°í·ÁÀÇ´ë)
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 14:10~14:30 MDMA and ketamine assisted psychotherapy for PTSD ¹ÚÁÖ¾ð(°è¿äº´¿ø)
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 13:20~13:45 Overview of resistant bipolar disorder ÀÓÀº¼º(½Å¼¼°èÈ¿º´¿ø)
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 13:45~14:10 Pharmacological treatment for resistant bipolar disorder ¼Á¤¼®(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 14:10~14:30 Non-pharmacological treatment for resistant bipolar disorder ¹®Àº¼ö(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 14:30~14:55 Applying personalized medicine principles to cognitive remediation (CR) for schizophrenia spectrum disorders ÀüÈ«ÁØ(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 14:55~15:20 Predictors of lithium responses in bipolar disorder ¹Ú¿µ¹Î(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 15:20~15:40 Neuropsychological and neuroimaging markers for recurrence of major depressive disorder °½Â°É(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 14:30~14:55 Overview of resistant depression ±è¿ø(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 14:55~15:20 Pharmacological treatment for resistant depression ¾çÁ¾Ã¶(ÀüºÏÀÇ´ë)
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 15:20~15:40 Non-pharmacological treatment for resistant depression ÀÌ°¼ö(Â÷ÀÇ°úÇдë)
ÈÞ½Ä 03¿ù 22ÀÏ 15:40~15:50 ÈÞ½Ä ()
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 15:50~16:15 Etiologic controversies in adult ADHD ¼ºÇü¸ð(Â÷ÀÇ°úÇдë)
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 16:15~16:40 Diagnostic controversies in adult ADHD ½É¼¼ÈÆ(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 16:40~17:00 Treatment controversies in adult ADHD È«Á¤¿Ï(Àͻ꺴¿ø)
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 15:50~16:15 Overview of resistant OCD ³ë´ë¿µ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 16:15~16:40 Pharmacological treatment for resistant OCD õÀºÁø(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 16:40~17:00 Non-pharmacological treatment for resistant OCD À̽ÂÀç(°æºÏÀÇ´ë)